PDF herunterladen
Thromb Haemost 1996; 76(04): 549-555
DOI: 10.1055/s-0038-1650621
Original Article
Schattauer GmbH Stuttgart

Inactivation of Factor XIa in Vivo: Studies in Chimpanzees and in Humans

Walter A Wuillemin
1   The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Clinical and Experimental Immunology, University of Amsterdam, Amsterdam
,
C Erik Hack
1   The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Clinical and Experimental Immunology, University of Amsterdam, Amsterdam
2   Department of Internal Medicine, Free University Hospital, Amsterdam
,
Wim K Bleeker
1   The Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Clinical and Experimental Immunology, University of Amsterdam, Amsterdam
,
Bart J Biemond
3   Center for Hemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, Academic Medical Center, Amsterdam
,
Marcel Levi
3   Center for Hemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, Academic Medical Center, Amsterdam
,
Hugo ten Cate
3   Center for Hemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, Academic Medical Center, Amsterdam
4   Slotervaart Ziekenhuis, Department of Internal Medicine, Amsterdam, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 04. April 1996

Accepted after revision 28. Juni 1996

Publikationsdatum:
10. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

C1-inhibitor (C1Inh), antithrombin III (ATIII), α1-antitrypsin (a1AT), and α2-antiplasmin (a2AP) are known inhibitors of factor XIa (FXIa). However, their precise contribution to FXIa inactivation in vivo is not known. We investigated FXIa inactivation in chimpanzees and assessed the contribution of these inhibitors to FXIa inactivation in patients with presumed FXI activation.

Chimpanzees were infused with FXIa and the various FXIa-FXIa inhibitor complexes formed were measured. Most of FXIa was complexed to C1Inh (68%), followed by a2AP (13%), a1AT (10%), and ATIII (9%). Analysis of the plasma elimination kinetics revealed a half-life time of clearance (t1/2) for the FXIa-FXIa inhibitor complexes of 95 to 104 min, except for FXIa-a1AT, which had a t1/2 of 349 min. Due to this long t1/2, FXIa-a1AT complexes were predicted to show the highest levels in plasma samples from patients with activation of FXI. This was indeed shown in patients with disseminated intravascular coagulation, recent myocardial infarction or unstable angina pectoris. We conclude from this study that in vivo C1Inh is the predominant inhibitor of FXIa, but that FXIa-a1 AT complexes due to their relatively long t1/2 may be the best parameter to assess FXI activation in clinical samples.

 

  • References

  • 1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-10370
    CrossrefPubMedGoogle Scholar
  • 2 Kitchens CS. Factor XI: a review of its biochemistry and deficiency. Semin Thromb Haemost 1991; 17: 55-72
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 3 Thompson RE, Mandle RJ, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-1380
    CrossrefPubMedGoogle Scholar
  • 4 Saito H, Goldsmith GHJ. Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay. Blood 1977; 50: 377-385
    PubMedGoogle Scholar
  • 5 Bouma BN, Griffin JH. Human blood coagulation factor XI. Purification, properties and mechanism of activation by activated factor XII. J Biol Chem 1977; 252: 6432-6437
    PubMedGoogle Scholar
  • 6 Bouma BN, Vlooswijk RAA, Griffin JH. Immunologic studies of human coagulation factor XI and its complex with high molecular weight kininogen. Blood 1983; 62: 1123-1131
    PubMedGoogle Scholar
  • 7 Komiyama Y, Nishikado H, Masuda M, Egawa H, Kobayashi N, Kobatake S, Matsuura S, Murata K. A rapid enzyme-linked immunosorbent assay for human factor XI. Thromb Res 1988; 50: 329-334
    CrossrefPubMedGoogle Scholar
  • 8 Kurachi K, Davie EW. Activation of human factor XI (plasma thromboplastin antecedent) by factor Xlla (activated Hageman factor). Biochemistry 1977; 16: 5831-5839
    CrossrefPubMedGoogle Scholar
  • 9 Colman RW. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 1984; 73: 1249-1253
    PubMedGoogle Scholar
  • 10 Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15
    PubMedGoogle Scholar
  • 11 Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912
    CrossrefPubMedGoogle Scholar
  • 12 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-7358
    PubMedGoogle Scholar
  • 13 van der Graaf F, Greengard JS, Bouma BN, Kerbiriou DM, Griffin JH. Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem 1983; 258: 9669-9675
    PubMedGoogle Scholar
  • 14 Fujikawa K, Chung DW, Hendrickson LE, Davie EW. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986; 25: 2417-2424
    CrossrefPubMedGoogle Scholar
  • 15 Soons H, Janssen-Claessen T, Tans G, Hemker HC. Inhibition of factor XIa by antithrombin III. Biochemistry 1987; 26: 4624-4629
    CrossrefPubMedGoogle Scholar
  • 16 Forbes CD, Pensky J, Ratnoff OD. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified Cl-inactivator. J Lab Clin Med 1970; 76: 809-815
    PubMedGoogle Scholar
  • 17 Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-357
    CrossrefPubMedGoogle Scholar
  • 18 Heck LW, Kaplan AP. Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by a 1-antitrypsin. J Exp Med 1974; 140: 1615-1629
    PubMedGoogle Scholar
  • 19 Saito H, Goldsmith GH, Moroi M, Aoki N. Inhibitory spectrum of ±2-plasmin inhibitor. Proc Natl Acad Sci USA 1979; 76: 2013-2017
    CrossrefPubMedGoogle Scholar
  • 20 Meijers JC, Kanters DH, Vlooswijk RA, van Erp HE, Hessing M, Bouma BN. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231-4237
    CrossrefPubMedGoogle Scholar
  • 21 Scott CF, Schapira M, James HL, Cohen AB, Colman RW. Inactivation of factor XIa by plasma protease inhibitors. Predominant role of β2-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 1982; 69: 844-852
    CrossrefPubMedGoogle Scholar
  • 22 Wuillemin WA, Minnema M, Meijers JCM, Roem D, Eerenberg AJM, Nuijens JH, ten Cate H, Hack CE. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for Cl-inhibitor. Blood 1995; 85: 1517-1526
    PubMedGoogle Scholar
  • 23 ten Cate H, Biemond BJ, Levi M, Wuillemin WA, Bauer KA, Barzegar S, Buller HR, Hack CE, ten Cate JW, Rosenberg RD. Factor XIa induced activation of the intrinsic cascade in vivo. Thromb Haemost 1996; 75: 445-449
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982; 60: 284-287
    PubMedGoogle Scholar
  • 25 ten Cate H, Brandjes DPM, Wolters HJ, van Deventer SJH. Disseminated intravascular coagulation: pathophysiology, diagnosis, and treatment. New Horizons 1993; 1: 312-323
    PubMedGoogle Scholar
  • 26 Dors DM, Nuijens JH, Huijbregts CC, Hack CE. A novel sensitive assay for functional factor XII based on the generation of kallikrein-C 1 -inhibitor complexes in factor XH-deficient plasma by glass-bound factor XII. Thromb Haemost 1992; 67: 644-648
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Hoogendoom H, Nesheim ME, Giles AR. A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. Blood 1990; 75: 2164-2171
    PubMedGoogle Scholar
  • 28 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor Vila in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212
    CrossrefPubMedGoogle Scholar
  • 29 Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120
    CrossrefPubMedGoogle Scholar
  • 30 Beeler DL, Marcum JA, Schiffman S, Rosenberg RD. Interaction of factor XIa and antithrombin in the presence and absence of heparin. Blood 1986; 67: 1488-1492
    PubMedGoogle Scholar
  • 31 Scott CF, Colman RW. Factors influencing the acceleration of human factor XIa inactivation by antithrombin III. Blood 1989; 73: 1873-1879
    PubMedGoogle Scholar
  • 32 Levi M, de Boer JP, Roem D, ten Cate JW, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992; 67: 111-116
    PubMedGoogle Scholar
  • 33 Ohlsson K, Laurell CB. The disappearance of enzyme-inhibitor complexes from the circulation of man. Clin Sci Mol Med 1976; 51: 87-92
    PubMedGoogle Scholar
  • 34 Espana F, Gruber A, Heeb MJ, Hanson SR, Harker LA, Griffin JH. In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 1991; 77: 1754-1760
    PubMedGoogle Scholar
  • 35 de Smet BJ, de Boer JP, Agterberg J, Rigter G, Bleeker WK, Hack CE. Clearance of human native, proteinase-complexed, and proteolytically inactivated Cl-inhibitor in rats. Blood 1993; 81: 56-61
    PubMedGoogle Scholar
  • 36 Berger Jr H, Kirstein CG, Orthner CL. Pharmacokinetics of activated protein C in guinea pigs. Blood 1991; 77: 2174-2184
    PubMedGoogle Scholar
  • 37 Fuchs HE, Shifman MA, Pizzo SV. In vivo catabolism of arproteinase inhibitor-trypsin, antithrombin III-thrombin and α2-macroglobulin-methylamine. Biochim Biophys Acta 1982; 716: 151-157
    CrossrefPubMedGoogle Scholar
  • 38 Pizzo SV, Mast AE, Feldman SR, Salvesen G. In vivo catabolism of arantichymotrypsin is mediated by the Serpin receptor which binds a j-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim’ Biophys Acta 1988; 967: 158-162
    PubMedGoogle Scholar
  • 39 Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990; 87: 3753-3757
    CrossrefPubMedGoogle Scholar
  • 40 Gonias SL, Fuchs HE, Pizzo SV. A unique pathway for the plasma elimination of α2-antiplasmin-protease complexes in mice. Thromb Haemost 1982; 48: 208-210
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Meijers JC, Vlooswijk RA, Bouma BN. Inhibition of human blood coagulation factor XIa by Cl inhibitor. Biochemistry 1988; 27: 959-963
    CrossrefPubMedGoogle Scholar
  • 42 Nishikado H, Komiyama Y, Masuda M, Egawa H, Murata K. Factor XIa-alpha 1 antitrypsin complex-elevation in the patients with DIC. Thromb Res 1986; 44: 489-501
    CrossrefPubMedGoogle Scholar
  • 43 Murakami T, Komiyama Y, Masuda M, Karakawa M, Iwasaka T, Takahashi H. Evaluation of factor XIa-al-antitrypsin in plasma, a contact phase-activated coagulation factor-inhibitor complex, in patients with coronary artery disease. Arterioscler Thromb Vase Biol 1995; 15: 1107-1113
    CrossrefPubMedGoogle Scholar